Effect of GLP-1 receptor agonists on body composition.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing published trials, meta-analyses, and animal studies
PubMed 41076575 · doi:10.1097/MED.0000000000000934
What was done
This narrative review synthesized evidence from clinical trials, meta-analyses, and rodent studies evaluating the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide and liraglutide, on fat mass, lean body mass (LBM), visceral adipose tissue (VAT), and resting energy expenditure (REE) in populations with and without type 2 diabetes.
What was found
The abstract reports no numerical data or effect sizes. It qualitatively describes marked fat mass loss with preferential VAT reduction, modest proportional declines in absolute LBM (with relative preservation or improvement of body composition proportions), and maintenance or increases in REE without accelerated sarcopenia. Drug cessation led to predictable weight regain primarily as fat mass.
Why it matters
It aggregates evidence indicating that GLP-1RA-driven weight reduction predominantly targets adipose and visceral depots rather than disproportionately eroding lean mass or depressing resting metabolic rate.
Limits
As a narrative review, it lacks systematic search criteria, risk-of-bias grading, and pooled statistical estimates in the abstract. Treatment durations, specific dosing regimens, and direct functional or muscle-strength outcomes are not detailed.
Cited by
- supports Weight loss on GLP-1s followed by regain results in a worse body composition because lean mass is lost during weight loss while mostly fat is gained back.